Of these, 627 patients who showed a suboptimal response after 8 weeks of treatment with olmesartan medoxomil 20 mg/day were randomised to receive olmesartan medoxomil 40 mg/day (n = 302 ...
Subjects underwent three consecutive 7-day treatment periods (A, B and C, respectively) during which they were randomly allocated to: olmesartan medoxomil 20mg (Sankyo Pharma GmbH, Munich ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback